- Home
- NBH vs VNDA Comparison
NBH vs VNDA Comparison
Compare NBH & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- VNDA
- Stock Information
- Founded
- NBH 2002
- VNDA 2002
- Country
- NBH United States
- VNDA United States
- Employees
- NBH N/A
- VNDA N/A
- Industry
- NBH Finance/Investors Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- VNDA Health Care
- Exchange
- NBH Nasdaq
- VNDA Nasdaq
- Market Cap
- NBH 300.6M
- VNDA 270.0M
- IPO Year
- NBH N/A
- VNDA 2006
- Fundamental
- Price
- NBH $10.42
- VNDA $4.36
- Analyst Decision
- NBH
- VNDA Strong Buy
- Analyst Count
- NBH 0
- VNDA 2
- Target Price
- NBH N/A
- VNDA $15.50
- AVG Volume (30 Days)
- NBH 85.9K
- VNDA 522.7K
- Earning Date
- NBH 01-01-0001
- VNDA 02-05-2025
- Dividend Yield
- NBH 4.34%
- VNDA N/A
- EPS Growth
- NBH N/A
- VNDA N/A
- EPS
- NBH 0.12
- VNDA N/A
- Revenue
- NBH N/A
- VNDA $190,858,000.00
- Revenue This Year
- NBH N/A
- VNDA $5.60
- Revenue Next Year
- NBH N/A
- VNDA $42.85
- P/E Ratio
- NBH $87.04
- VNDA N/A
- Revenue Growth
- NBH N/A
- VNDA N/A
- 52 Week Low
- NBH $8.75
- VNDA $3.46
- 52 Week High
- NBH $11.01
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- NBH 50.78
- VNDA 34.28
- Support Level
- NBH $10.11
- VNDA $4.77
- Resistance Level
- NBH $10.45
- VNDA $4.95
- Average True Range (ATR)
- NBH 0.09
- VNDA 0.15
- MACD
- NBH 0.03
- VNDA -0.04
- Stochastic Oscillator
- NBH 91.18
- VNDA 9.09
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Intermediate Muni Fund is a closed-end management investment company that invests mainly in municipal securities. It aims to provide common stockholders a high level of current income exempt from Federal income tax.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.